

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2023/2024 influenza season**

as of May 23, 2024

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	1 (0.3%)	2 (0.2%)	2 (0.2%)	0	0	194 (100%)	4 (0.7%)	0	0	0	0	258 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	363	842	842	191	191	194	594	255	255	255	255	258	181	127	127	127	127
<b>Number of viruses reported</b>	1,848						3,385						1,644				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.